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Abstract
Reports showing susceptibility of multidrug resistant (MDR) cancer cells to immune effectors,
together with P-glycoprotein (P-gp) expression in immune effector subsets, including immature
natural killer (NK) cells, and some activated T cells, suggest P-gp or some changes associated with
it, have implications in immune-mediated mechanisms. A series of experiments were done to
determine the nature of alterations associated with susceptibility to immune effector cells of MDR
tumor cells. A cell line isolated from the malignant pleural effusion of a breast cancer patient was
transfected with human and murine MDR1 genes, and four variants with different levels of MDR
were obtained. Lymphokine-activated killer (LAK) activity was measured by a 51Chromium release,
and conjugate formation assays. MDR1 transfectant P-gp+ breast carcinoma lines had increased LAK
susceptibility compared to their parent line. Some part of the increased LAK susceptibility of drug-
resistant cell lines was at the binding/recognition level as shown by conjugate formation assays. This
suggests that differences may exist between paired cell lines with respect to the expression of cell
adhesion molecules (CAMs). Monoclonal antibodies (mAbs) to CAMs and flow cytometry were
used to quantitate these antigens. The CAMs studied were those previously found to be
upregulated by stimulating NK cells with (interleukin-2) IL-2; ICAM-1 (CD54), LFA-3 (CD58), N-
CAM (CD56), and the β chain of LFA-1 (CD18). Although no differences in these CAMs were
found between the breast carcinoma line and its MDR1-transfected variants, the target
susceptibility results given above suggest that IL-2 treatment could be effective in combination with
current protocols using chemotherapeutics, monoclonal antibodies (mAbs) and stem cell
transplantation.
Background
Breast cancer is a serious health concern and a major pub-
lic health challenge with an incidence of 217.500 and
breast cancer deaths of 40.600 in USA being estimated in
2004 [1]. The primary treatment of early stage breast can-
cer is by surgery and radiation therapy, and a cure is fre-
quently achieved if the cancer has not spread. The
addition of chemotherapy can increase the long-term sur-
vival of patients with breast cancer, presumably by killing
cancer cells beyond the operative field, and the use of
chemotherapy after recurrence of breast cancer can pro-
vide significant palliation. However, post-chemotherapy
recurrence of cancer that is resistant to further chemother-
apeutic measures is a major problem. Low expression of
the MDR1 and multidrug resistance-associated protein 1
(MRP1) genes is observed in primary breast cancers, how-
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ever MDR1 expression is increased in tumors refractory to
chemotherapy, in lobular breast carcinoma and in tumors
from the patients below age 50, all of which are known to
be associated with poor prognosis [2-4] The MDR1 gene
frequently becomes amplified and its mRNA is overex-
pressed in cells selected for resistance to drugs such as dox-
orubicin, daunomycin, vinca alkaloids, taxanes, and
actinomycin D. Anthracyclines such as doxorubicin, tax-
anes such as paclitaxel and the vinca alkaloids such as
vinorelbine are very active agents used frequently in the
treatment of breast cancer [5].
One aspect of breast cancer biology that hinders cure is
tumor cell heterogeneity and phenotypic variability.
Some tumor cells may be killed by chemotherapy, but the
ability of a tumor cell population to adapt to a new envi-
ronment results in progression of the disease. This arises
from either the tumor cells that are already resistant to the
therapeutic drug or tumor cells that develop resistance
during the course of the treatment.
After the impressive progress in the understanding of the
basic tumor biology of the breast cancer, demand for
additional markers of biologic relevance for the predic-
tion of breast cancer outcome and of response to various
chemotherapy, radiotherapy and immunotherapy regi-
mens has increased in the recent years.
Over the ensuing decade, systemic administration of c-
erbB-2 monoclonal antibody trastuzumab in patients
with c-erbB-2 over-expressing tumors was found to pro-
duce objective regressions in 11 to 26 percent of patients
with metastatic breast cancer [6,7]. Recently, four large
multicenter designed to test the role of trastuzumab as
adjuvant therapy after surgical treatment of primary breast
cancer found an absolute benefit of 6 to 8 percent at two
years and 18 percent by four years [6,8,9]. This is particu-
larly impressive given the evidence that c-erbB-2 gene and
protein abnormalities in breast cancer predict poor prog-
nosis and resistance to tamoxifen therapy and chemother-
apy regimens such as CMF (cyclophosphamide,
methotrexate, 5-fluorouracil) [7,10] However, the ampli-
fication and overexpression of c-erbB-2 proto-oncogene
has been described in approximately 25–30 % of breast
carcinomas [11,12].
LAK cell immunotherapy has been shown to have the
potential to eradicate P-gp+ MDR tumor cell populations
in ovarian, SCLC, malignant melanoma and renal cell car-
cinoma [13-16]. In addition to P-gp+ MDR tumor cell
populations, c-erbB2(+) positive breast cancer cells may
be eradicated to a better extent with c-erbB2 mAb + LAK
cells since LAK cells have strong antibody-dependent cell-
mediated cytotoxic (ADCC) activity [16].
The objectives of the current study were:
1. To quantitate the LAK cell-mediated lysis (CML) sus-
ceptibility of drug sensitive and drug resistant breast can-
cer cell lines.
2. To study the binding/recognition step of LAK CML in
these cell lines and its contribution to differences in LAK
CML of the paired sensitive and MDR cell lines.
3. To measure the level of expression of CAMs shown to
be involved in the binding/recognition step of lysis and to
compare these levels within the paired cell line groups.
Results
Human LAK cell-mediated lysis
Peripheral blood lymphocytes collected from normal vol-
unteers were activated with human recombinant inter-
leukin 2 and tested for LAK cell activity against the drug
sensitive human breast carcinoma cell line MDA-MB-231,
and its MDR-transfected variants MPAM-26, MPAHS-1-
10, MPAHS-1-300, and MPAHS-DOX150. LAK cell cyto-
toxicity was also tested against the NK-sensitive, LAK-sen-
sitive cell line K562, and the NK-resistant, LAK-sensitive
RAJI cell line. LAK cell-mediated cytotoxicity against target
cells was evaluated by an 18 hr 51Cr-release assay.
The percent chromium release, lytic unit values and cyto-
toxicity relative to the parental line were calculated in
order to determine if there were differences in LAK cell
susceptibility between paired cell lines. The susceptibility
of MDA-MB-231 and its MDR variants to LAK cell lysis is
shown in Fig. 1 as percent cell-mediated lysis (or percent
specific 51Cr release), and in Fig. 2 as lytic units.
In these experiments, the murine MDR1-transfected vari-
ant MPAM-26 and the human P-gp+ transfected lines
MPAHS-1-10, MPAHS-1-300 and MPAHS-DOX150 were
found to have a four to five fold increased sensitivity to
LAK CML in comparison to the drug sensitive parent line
MDA-MB-231. Lysis of MPAM-26 was significantly higher
than that of MDA-MB-231, as shown by both Student's
paired "t" test (p = 0.04, 1-sided) (log-transformed data)
and the Wilcoxon signed-ranks matched-pairs non-para-
metric test (p = 0.02, 2-sided). The correlation between
the two sets of paired data was r = 0.95 for the log-trans-
formed data. Lysis of MPAHS-1-10 was significantly
higher than that of MDA-MB-231, as determined by both
Student's paired "t" test (p = 0.008, 2-sided) (log-trans-
formed data) and the Wilcoxon signed-ranks matched-
pairs non-parametric test (p = 0.003, 2-sided). The corre-
lation between the two sets of paired data was r = 0.96 for
the log-transformed data. Lysis of MPAHS-DOX-150 was
also significantly higher than that of MDA-MB-231, as
determined by the Wilcoxon signed-ranks matched-pairsCancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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non-parametric test (p = 0.03, 2-sided), and by the Stu-
dent's paired "t" test (p = 0.05, 1-sided) (log-transformed
data). All of the above statistics were calculated with n =
15.
Effect of P-gp expression on 51Cr efflux
P-gp is postulated to function as an energy-dependent
efflux pump in MDR resistant cells. Therefore, 51Cr might
be actively pumped out of MDR cells during the 51Cr-
release assay by the P-gp. This might complicate the inter-
pretation of changes in the susceptibility of P-gp+ cells to
LAK CML. In order to examine whether 51Cr is actively
pumped out of MDR cells by P-gp during the assay, the
"spontaneous" release (SR) of 51Cr from MDR breast cell
lines and their sensitive counterpart was determined
(Table 1). The SR value represents the release of 51Cr from
labelled cells incubated in medium alone (without LAK
effector cells) for the duration of the assay. MDR carci-
noma cell lines exhibited unchanged SR with respect to
their sensitive counterparts. It is concluded that, in gen-
eral, P-gp expression was not associated with any signifi-
cant change in spontaneous 51Cr release during the time
Susceptibility of MDA-MB-231 breast carcinoma cell lines to human LAK CML (51Chromium-release data)  1
Susceptibility of MDA-MB-231 breast carcinoma cell lines to human LAK CML (51Chromium-release data). 2 × 
106 PBMC/ml were incubated with 1000 U/ml human rIL-2 in RPMI 1640 containing 10% autologous plasma in a total volume of 
10 ml. After 5 days, these cells were harvested and set up in an 18 hr 51Cr-release assay to measure the cytotoxicity against 
MDA-MB-231 (drug-sensitive breast carcinoma cell line), MPAM-26 (murine MDR-1 transfected), and Vcr10 (MPAHS-1-10), 
Vcr300 (MPAHS-1-300), Dox150 (MPAHS-DOX150), human P-gp transfected multidrug resistant variants of MDA-MB-231. 
Percent specific cell-mediated lysis was plotted against effector/target ratio based on data obtained from one experiment rep-
resentative of 15 independent experiments performed by three independent investigators. The data from the 15 experiments 
were converted to lytic units and tested for significant difference (see text).Cancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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of experiment. These results are in agreement with similar
results for the effect of P-gp expression on 51Cr efflux in
MDR SCLC and ovarian carcinoma cell lines [15,16].
Effect of P-gp expression on LAK cell-mediated 
cytotoxicity at the binding/recognition level
In order to examine whether the increased or decreased
LAK susceptibility of MDR breast cell lines is at the bind-
ing/recognition or post-binding level, conjugate forma-
tion assays were performed. PBMCs were activated with
human rIL-2 and tested for LAK cell binding activity
against the breast carcinoma cell line MDA-MB-231 and
its MDR variants MPAM 26, MPAHS-1-10, MPAHS-1-300,
and MPAHS-DOX150. The data obtained from 4 separate
experiments are shown in Fig. 3.
All of the MDR variants had increased LAK:Target binding
that was statistically significant. The parent line had
approximately 27% of LAK cells bound to it versus 41% to
61% for the MDR cell lines. MPAM 26, MPAHS-1-10 and
MPAHS-DOX150 had 50% to 80% increased binding
compared to the drug sensitive parent line and MPAHS-1-
300 had approximately 120% increased binding. The
results are in agreement with previous studies for the
SCLC and ovarian carcinoma cell lines [15,16]. Increased
LAK:target conjugation of MDR cell lines compared to
drug-sensitive parents suggest that the increased suscepti-
Human LAK cell sensitivity of MDA-MB-231 breast carcinoma cell lines expressed as LU Figure 2
Human LAK cell sensitivity of MDA-MB-231 breast carcinoma cell lines expressed as LU. Using the same experi-
mental design as in Fig. 1, results obtained from LAK CML experiments with MDA-MB-231 breast carcinoma cell lines are 
demonstrated as lytic units ± standard deviation. 1 = MDA-MB-231 (drug-sensitive breast carcinoma cell line), 2 = MPAM-26 
(murine P-gp transfected variant of MDA-MB-231), 3 = MPAHS-1-10 (human P-gp transfected variant of MDA-MB-231), 4 = 
MPAHS-1-300 (human P-gp transfected variant of MDA-MB-231),5 = MPAHS-DOX150 (human P-gp transfected variant of 
MDA-MB-231). The results shown are from an experiment representative of 15 independent experiments, performed by three 
independent investigators. LAK effectors were from three different donors. Results are expressed as LU/106. Each lytic unit 
value is derived from 8 effector/target (E/T) ratios as described in the Methods.Cancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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bility to LAK CML of these MDR cell lines, compared to its
drug sensitive parental counterpart, is due mainly to
greater binding/recognition.
Adhesion molecule expression and correlation with LAK 
CML
In order to determine whether or not differences at the
binding/recognition step of LAK CML are associated with
differences observed in the LAK susceptibility of drug sen-
sitive and resistant paired breast cell lines, the level of sur-
face expression of adhesion molecules ICAM-1, LFA-3, N-
CAM, and CD18, as well as P-gp and HLA Class I were
measured in conjunction with the LAK CML of the cell
lines. The level of expression of the surface molecules was
measured using commercially available mAbs and flow
cytometric analysis. Data are expressed in terms of percent
positive cells and monoclonal antibody binding sites val-
ues calculated as described in the Methods.
There was no significant difference in the expression of
CAMs or HLA Class I antigen between the drug sensitive
parent line MDA-MB-231 and its MDR1-transfected coun-
terparts. Differences were observed in the level of P-gp
expression. P-gp determined by MRK16 mAb was not
expressed on the parent line or on murine MDR1-trans-
fected MPAM 26. However, when MDA-MB-231 and
MPAM-26 cells were stained with mAb JSB-1 which,
unlike MRK16, recognizes a conserved cytoplasmic
epitope of P-gp [17], P-gp expression on MPAM-26 was
observed (data not shown).
MPAHS-1-300 and MPAHS-DOX150 had significantly
increased levels of P-gp compared to the parent line (p <
0.001, Student's "t"-test, 2-sided), and MPAHS-1-10 was
higher at p = 0.03 (Student's "t"-test, 1-sided). Relative
Fluorescence Intensity (RFI) values were calculated
according to the equation : RFI = RFI (test sample) – RFI
(negative control).
Samples were prepared by incubating the cell lines with
each mAb listed followed by FITC-labeled secondary Ab.
Samples were read on a Becton Dickinson FACS IV. Anti-
CD54 (ICAM-1), anti-CD58 (LFA-3), anti-CD56 (N-
CAM) or Leu19, anti-CD18, which is the β chain of LFA-
1, MAC-1 and P150/95 were the anti-CAM mAbs studied.
Levels of anti-P-gp mAb MRK16, which labels the surface
epitope of P-gp, and W6.32 (anti-HLA-A,B,C) were also
measured.
The percentage of cells expressing surface antigen was
determined using flow cytometric analysis. A lower gate
channel was set on the negative control sample so that 5%
of the total cells lay above the gate. The same gate was set
on each test sample, and the percentage of cells which lay
above the gate was determined. This number, after 5%
was subtracted from it, was reported as the percent posi-
tive cells in each test sample. The data are shown in Table
2. The percent positive cells was directly related to the RFI
of the positive cell population.
Quantitation of the Ab binding sites on cell surfaces
In order to assess the absolute quantitative level of expres-
sion of the different surface antigens studied, the number
of actual Ab binding sites on the cell surface was deter-
mined. Differences exist between the number of second-
ary antibodies that may bind to a primary Ab and thus,
differences exist in the measure of fluorescence obtained.
In order to make accurate comparisons between the
expression of different surface antigens and to obtain val-
ues that are consistent and comparable between laborato-
ries, it is necessary to correct for this difference. In order to
accomplish this, a microbead quantitation system was
used. After the standardization of the FACS with cali-
brated fluorescence microbeads, the effective fluores-
cence-to-protein ratios for each mAb are calculated.
Values obtained from three separate experiments for the
MDA-MB-231 breast carcinoma cell line series are pre-
sented in Table 2 (above – "B" rows).
Discussion
In this study, the following observations were made:
1. Three human MDR1-transfected, and one mouse
MDR1-transfected breast carcinoma cell lines had
increased sensitivity to LAK cell-mediated lysis compared
with the parental line. The increases of these targets were
statistically significant.
2. There were no significant differences in the expression
of adhesion molecules ICAM-1, LFA-3, CD18, and CD56
or HLA Class I antigen between drug-sensitive and MDR
breast carcinoma paired cell lines.
Table 1: Spontaneous Release (SR) exhibited by MDR and drug-
sensitive breast carcinoma cell lines
Cell Line SR SE n
MDA-MB-231 16.1 3.3 8
MPAM 26 17.1 6.6 10
MPAHS-1-10 17.0 1.9 8
MPAHS-1-300 19.2 4.2 8
MPAHS-DOX150 18.7 5.7 8
SR = Spontaneous 51Cr release during 18 hour assay in wells which 
contain targets, but not LAK cells. SR is expressed as % of the 
maximum.
SE = Standard error. n = Number of independent experimentsCancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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3. The MDR breast tumor cell lines demonstrated
increased binding to LAK cells in comparison to the par-
ent line.
Immunotherapy using LAK cells is a candidate treatment
modality which may be effective in patients with tumors
that are resistant to chemotherapy in breast, ovarian, and
colon carcinoma, small cell lung cancer and melanoma
[14-16,18-20]. There is a need for more studies on LAK
immunotherapy assessing the susceptibility of tumors to
LAK CML and determining predictive factors for the
potential success of immunotherapy. Previous studies by
us and others in the literature (for a review please see
Table 2 of reference paper [14]) suggest that P-gp expres-
sion or various changes associated with P-gp increase the
susceptibility of MDR tumor cell lines to LAK cell medi-
ated cytotoxicity. After observing the increased lym-
phokine-activated killer (LAK) cell sensitivity of the
multidrug resistant (MDR) P-gp(+) small cell lung carci-
noma line H69/LX4, but not the multidrug resistant-asso-
ciated protein(+), P-gp(-) and glutathione-S-transferase pi
(+) variant H69/AR compared to the parental line H69
LAK cell binding of MDA-MB-231 breast carcinoma cell lines as shown by conjugate formation assay Figure 3
LAK cell binding of MDA-MB-231 breast carcinoma cell lines as shown by conjugate formation assay. 1 × 105 
LAK cells (0.1 ml) and 1 × 105 target cells (0.1 ml) were mixed in the same tube, centrifuged for 2 min at 500 g and incubated 
at 37°C for 10 min. The cells stained with trypan blue were observed under phase contrast microscope. 2 LAK cells forming a 
conjugate with a live tumor cell is demonstrated in Fig. 4. A LAK cell was observed to form a conjugate with a blue-dead tumor 
cell is visible in Fig. 5. Two blue-dead tumor cells are also seen in this picture. The percentage of LAK cells attached to the tar-
gets and vice versa was counted in a modified Cunningham chamber. And the data represent the arithmetic mean ± standard 
deviation of the mean percent LAK cells conjugated to targets (LAK:Target) of 4 independent experiments. The percentage of 
LAK:Target cell conjugates formed by the MDR breast carcinoma cell lines was found to be higher than that formed by the 
drug-sensitive parent cell line MDA-MB-231. This increase was statistically significant at p < 0.05 for MPAM 26, MPAHS-1-10, 
and MPAHS-DOX150, and at p = 0.01 for MPAHS-1-300 (Student's paired "t" test, 1-sided). 1 = MDA-MB-231 2 = MPAM 26 3 
= MPAHS-1-10 4 = MPAHS-1-300 5 = MPAHS-DOX-150Cancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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[15], we chose to investigate LAK cell susceptibility of
mouse and human multi-drug resistance 1 (MDR1) gene
transfected MDR cell lines. Since the MDR cell line vari-
ants of SCLC model in the article above were developed
by stepwise increments of chemotherapeutics, there is a
concern that the results might have been affected from
various changes other than P-gp that the cell line variants
might have acquired during this lengthy period. In order
to assess this possibility, we analyzed 3 human MDR1-
transfected and one mouse MDR1-transfected variants of
a drug-sensitive breast cancer line MDA-MB-231 in this
paper.
In order to eliminate factors other than P-gp that may
develop during the long time necessary for a cell line to
develop P-gp+ MDR during incremental drug challenge of
parental drug sensitive cell lines; human and murine
MDR1 cDNA were transfected into a metastatic breast car-
cinoma cell line and P-gp was allowed to demonstrate
itself under the selecting pressure of 3 different drugs at
four different concentrations in a short time compared to
the previous MDR lines developed without MDR1 trans-
fection. Increased LAK susceptibility was observed in all of
the four MDR1-transfected cell lines. It should be empha-
sized that increased LAK susceptibility was observed for
both human and murine P-gp expressing targets. Previ-
ously, increased human LAK effector killing against P-gp+
Chinese hamster ovary target cell lines was also shown
[16]. In the same study increased LAK susceptibility of
human P-gp expressing tumor targets against murine LAK
cells was demonstrated in a similar fashion. These results
suggest increased LAK susceptibility for P-gp (+) targets-
crossed species barriers for both effectors and targets
among mammals.
Could this increased LAK susceptibility of P-gp+ cells be
due to a change in adhesion molecules? CAMs may bind
either to self (homophilic adhesion) or to other ligands
(heterophilic adhesion). After in vitro incubation with IL-
2, human NK cells demonstrated four- to sixfold increases
in surface levels of CD18, CD54, CD58, and CD56 [21].
Furthermore, essentially all NK cells became CD54+
Table 2: P-gp and adhesion molecule expression of MDR1-transfected human breast carcinoma cell lines as percent positive cells, and 
mAb binding sites (× 104)
MDA-MB MPAM-26 MPAH1-10 MPAH1-300 MPAHDOX
MRK16 = A 12.07 8.52 30.57 56.47 78.50
s.d. 4.10 1.62 10.85 3.20 9.68
MRK16 = B 5.45 3.00 4.41 12.85 38.36
s.d 0.21 0.56 0.35 2.79 10.23
ICAM-1 = A 58.65 59.39 62.63 55.13 76.36
s.d. 1.79 2.03 4.56 7.44 1.41
ICAM1 = B 16.43 13.36 12.66 19.00 35.54
s.d. 1.20 3.48 4.80 8.81 12.25
LFA-3 = A 82.37 83.12 83.30 84.12 89.38
s.d. 2.31 1.27 6.71 4.84 1.42
LFA-3 = B 23.65 24.65 18.08 33.22 53.66
s.d. 11.36 3.31 3.41 6.20 9.64
CD18 = A 2.44 0.13 9.69 18.43 0.17
s.d. 1.35 3.52 2.52 3.26 0.93
CD18 = B 7.44 5.66 5.24 7.77 7.58
s.d. 1.31 1.72 1.35 1.57 1.76
CD56 = A 3.72 0.58 4.18 0.44 0.33
s.d. 2.13 0.44 5.88 0.75 0.57
CD56 = B 6.92 4.90 3.97 5.97 5.93
s.d. 0.91 1.20 0.81 1.29 0.07
A = Percent positive cells
B = mAb binding sites (× 104/cell)Cancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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within 3 days of exposure to IL-2. In addition, IL-2 dra-
matically increased the levels of CD56 and CD58 on NK
cells. In contrast, T cells did not demonstrate comparable
up-regulation of these CAMs after incubation with IL-2.
Increases in NK cell CAM expression were associated with
enhanced formation of effector to target cell (E/T) conju-
gates, enhanced killing of NK-sensitive targets, and the
induction of cytotoxicity for previously NK-resistant tar-
gets (LAK activity).
In 1991, a new association between P-gp expression in
invasive colon carcinoma cells and increased metastases
to lymph nodes was described [22]. Although the adhe-
sion profiles of P-gp have not been examined in detail,
several observations raised the possibility that P-gp may
influence cell adhesion and, as a result of this, the process
may be involved in cancer dissemination and possibly,
the sensitivity of tumor cells to LAK CML. Similarly, P-gp
expression was accompanied by increased homotypic
adhesion in epidermoid carcinoma cells in tissue culture
[23,24]. In 1990, Grogan et al. observed a relationship
between the hyperexpression of both P-gp and N-CAM
molecules in myeloma plasma cells in tissue culture [25].
These cells showed increased homotypic adhesion. How-
ever, N-CAM and P-gp co-modulation was not observed
in our study (Table 2).
MHC, ICAM-1, LFA-3, NCAM and CD18 were examined
in MDR1-transfected breast carcinoma cell lines in this
study, and no significant correlations were found for the
breast carcinoma cell lines neither between LAK CML and
these CAM expressions, nor between LAK CML and MHC
Class I molecule expression. Similar results were also
observed previously in MDR P-gp+ the ovarian carcinoma
cell line 2780.AD645 and SCLC line H69/LX4 [15,16].
Another possibility for the mechanism may involve gan-
gliosides. In 1991, Mazzoni et al. found an involvement
of cell membrane gangliosides in the development of the
A2780-Doxorubicin MDR phenotype, and suggested a
possible involvement of the ganglioside GD1a in the
increased sensitivity of MDR cells to immuno-mediated
cytolysis [26]. Indirect mechanisms related to the bio-
chemical alterations occurring in MDR neoplastic cells
may influence LAK CML susceptibility. A significant
increase of Ca++/phosphokinase C (PKC) activity, fre-
quently present in MDR cells [27] could enhance the cyto-
toxic effects of cytokine(s) released by activated
lymphocytes, since such a release is preceded by an influx
of Ca++ and PKC involvement [28]. Alterations of mem-
brane fluidity due to phospholipid changes associated
with P-gp expression in MDR tumor cells may lead to fra-
gility of the cells, resulting in increased susceptibility to
released cytotoxins [29,30].
The differentiation stage of tumor cells could also influ-
ence susceptibility of target cells. A decrease of NK sensi-
tivity is detectable after induction of a more differentiated
phenotype in colon-carcinoma lines by treatment with
differentiating agents [31] or by transfection with onco-
genes [32]. The expression of adhesion or adhesion-like
molecules and the differentiation stage of the target cells
appear to be related to each other [20]
For MDR1-transfected breast carcinoma cell lines, the
increased binding of MDR cell lines in comparison to the
sensitive parent line for LAK:Target binding suggests that
differences in the LAK cell-mediated lytic susceptibility of
these cells are due in part to differences at the binding/rec-
ognition level.
The possible increased LAK susceptibility and binding of
P-gp(+) MDR metastatic breast cancer cells as suggested in
this paper encourages studies toward mAbs and LAK cells
for the treatment of breast cancer patients since LAK cells
have strong ADCC. The development of "designer" mAbs,
chimeric mAb to particular antigens and receptors, and
their potential to target cancer cells and enhance their sus-
ceptibility to the effector arm of the immune system are
currently providing important new opportunities. The
potential for the use of monoclonal antibodies such as P-
gp and C-erb-B2 for the better therapeutic efficacy of LAK
immunotherapy in breast cancer is particularly encourag-
ing.
Conclusion
Our results demonstrated that four MDR1-gene trans-
fected metastatic breast carcinoma cell lines have
increased susceptibility and binding to the lymphokine-
activated killer cells. Interleukin-2 administration seems
to be a promising chemoimmunotherapy improving
modality in MDR1 over-expressing tumors.
Methods
Media and reagents
Unless otherwise indicated, media used to culture cell
lines consisted of RPMI 1640 containing 10% FCS supple-
mented with 10 mM L-glutamine (Gibco/BRL, Grand
Island, NY). Media used for the generation of LAK cells
consisted of culture media without FCS, supplemented
with 10% autologous plasma. Recombinant IL-2 was used
at a concentration of 1,000 U/ml (Cetus Corp., Emery-
ville, CA), which had been pre-determined to yield maxi-
mum LAK cell generation. Vincristine and doxorubicin
were purchased from Sigma, St. Louis, MO. Geneticin was
purchased from Gibco/BRL.
Monoclonal antibodies
Anti-CD54 (ICAM-1) and anti-CD58 (LFA-3) were pur-
chased from AMAC Inc., Westbrook, ME, anti-CD56 (N-Cancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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CAM) was purchased from Becton Dickinson, Mountain
View, CA, and anti-CD18 (β chain of LFA-1) was pur-
chased from Dakopatts, Glostrup, Denmark. Anti-P-gp
mAb MRK16, which labels the first extracellular domain
of P-gp which is heavily N-glycosylated and shows the
least homology between human and murine counterparts
[33] was a generous gift from Dr. T. Tsuruo, Hoechst,
Japan. Therefore MRK16 mAb is only reactive with P-gp of
human class I isoform (MDR1), but not with the human
class III isoform, or other classes of P-glycoproteins from
hamster, mouse, monkey, horse, pig, cow, and rabbit
[34]. The negative control used was Coulter anti-IgM
(Coulter, Hialeah, FL). The secondary antibody used was
the F(ab')2 fragment of goat anti-mouse Ig (IgG, IgA, IgM)
(Cappel Labs, Cooper Biomedical Inc., Westchester, PA).
Preparation of peripheral blood lymphocytes (PBL) and 
LAK cell generation
Venous blood was collected from healthy donors in
heparinized Vacutainer tubes. Mononuclear cells were
prepared by centrifugation (850 g, 15 min) over Ficoll-
Isopaque and were depleted of monocytes by incubation
on autologous plasma coated plastic dishes for one hour
at 37°C. These cells were recognized as PBL and were used
in NK studies. PBL (1–2 × 106/mL) were incubated in 25
cm3 cell culture flasks (Corning) for 5–8 days in a 5% CO2
environment at 37°C with RPMI medium containing 10
mM L-glutamine, 10% autologous serum and 1000 U/mL
human recombinant IL-2, and were used as LAK effectors
[35]. LAK cells harvested after this procedure is demon-
strated in LAK cells file ' [see Additional file 1]'.
LAK cell binding of MDA-MB-231 breast carcinoma cells Figure 4
LAK cell binding of MDA-MB-231 breast carcinoma cells. 1 × 105 LAK cells (0.1 ml) and 1 × 105 target cells (0.1 ml) 
were mixed in the same tube, centrifuged for 2 min at 500 g and incubated at 37°C for 10 min. The cells stained with trypan 
blue were observed under phase contrast microscope. 2 LAK cells forming a conjugate with a live tumor cell is demonstrated.Cancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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Cell lines and transfection
The human poorly-differentiated, estrogen receptor-nega-
tive and hormone-insensitive metastatic breast carcinoma
cell line MDA-MB-231 (ATCC HTB26), which was iso-
lated from pleural metastases of a woman with breast can-
cer [36,37] was transfected with murine or human P-gp
cDNA resulting in the drug resistant variants MPAM-26,
MPAHS-1-10, MPAHS-1-300, and MPAHS-DOX150.
Briefly, exponentially growing MDÁ-MB-231 cells were
transfected with PSKGA, which has a full length human
MDR1 cDNÁ, and MDR1 cDNÁ containing plasmiä
pGEM-4(ATCC clone designation pHDR5A). according to
calcium phosphate precipitation method [38]. Then, 16
hours later transfected cells were subcultured in selective
medium containing 400 microgram/ml geneticin (G418,
Gibco). After first selection, copy numbers of MDR1 gene
were amplified under stepwise increasing concentrations
of doxorubicin, and vincristine.
Cells were split using EDTA (Gibco/BRL) at 80% conflu-
ence. Cells were fed 2 times a week. The continuous cell
line drug supplements were as follows: MPAM-26 G418
(Geneticin, Gibco) 400 µg/ml; MPAHS-1-10 Vincristine
Sulfate (Sigma) 10 ng/ml; MPAHS-1-300 Vincristine Sul-
fate (Sigma) 300 ng/ml; MPAHS-DOX150 Doxorubicin
Hydrochloride (Sigma) 150 ng/ml.
K562 (NK-sensitive, LAK-sensitive standard) is a human
erythroleukemia cell line isolated from a pleural effusion
of a patient with chronic myelogenous leukemia in blast
crisis [39]. K562 was obtained from the ATCC (# CCL
243, Rockville, MD). All cell lines were maintained by
LAK cell binding of MDA-MB-231 breast carcinoma cells Figure 5
LAK cell binding of MDA-MB-231 breast carcinoma cells. 1 × 105 LAK cells (0.1 ml) and 1 × 105 target cells (0.1 ml) 
were mixed in the same tube, centrifuged for 2 min at 500 g and incubated at 37°C for 10 min. The cells stained with trypan 
blue were observed under phase contrast microscope. A LAK cell was observed to form a conjugate with a blue-dead tumor 
cell. Two blue-dead tumor cells are also seen in this picture.Cancer Cell International 2006, 6:24 http://www.cancerci.com/content/6/1/24
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continuous culture as described, and periodically tested
for mycoplasma contamination by the DAPI (4',6-Dia-
midino-2-phenylindole) (Sigma Chemical Co.) fluores-
cence assay [40].
Cell line treatment prior to experimentation
In order to create similar conditions for the comparison of
the cytotoxic cell susceptibility and adhesion molecule
expression of drug-sensitive vs drug-resistant pairs, breast
target cell lines were resuspended at a concentration of
0.3–0.6 × 106 cells/flask in new flasks 5 days prior to the
experiments in drug-free medium. The culture medium
was changed each of the 5 days, and the experiments were
done while the target cells were in the exponential growth
phase.
Cytotoxicity assays
LAK activity was assessed in an 18 hr 51Cr release assay
[41] against the standard target K562, and MDA-MB-231
(human adenocarcinoma breast, P-gp-), MPAM 26
(murine MDR1-transfected), MPAHS-1-10, MPAHS-1-
300, MPAHS-DOX150 (human MDR1-transfected). Sin-
gle cell suspensions of target cells in a logarithmic growth
phase were labelled with 51Cr. Effector/target cell concen-
trations were adjusted to 40:1, 20:1, 10:1, 5:1, 2.5:1,
1.25:1, 0.62:1, and 0.31:1 in 96-well microtiter plates,
then incubated for 18 hours at 37°C. The plates were then
centrifuged (200 g, 10 min), and supernatants from each
well were counted in a Beckman 5500 gamma-counter.
Percent specific release of each target was calculated with
following formula.
cpm = radioactivity count per minute in each well.
Data processing
51Cr release data were expressed in lytic units (LU) calcu-
lated according to the equation: y = A(1-e-kx) where y =
percent of chromium release, x = Effector/target cell ratio,
A = Maximal lysis by effector cells, k = a constant propor-
tional to effector cell number, and equal to the negative
slope of the target survival curve obtained by plotting ln
(A-y) vs x [41]. Statistical significance analysis was done
by using the SPSS program.
Fluorescence activated cell sorter analysis
0.25–0.5 × 106 cells were placed in 12 × 75 mm test tubes
(Falcon Labware Inc., Oxnard, CA) and centrifuged at 300
g for 6 min. The supernatant was removed and the mAb
was added, tubes were vortexed and then incubated on ice
in the cold room for 30–45 min. The concentrations of
mAb added were: anti-ICAM-1 at 20 µl/test (5 × 105 cells/
test), anti-LFA-3 at 10 µl/test (5 × 105 cells/test), anti-N-
CAM at 20 µl/106 cells, anti-CD18 at 20 µl of 206 µg/ml
stock, MRK16 at 10 µg/ml (5 × 105 cells) and W6.32
(ascites) diluted 1:500 (5 × 105 cells). Following this they
were washed twice by centrifugation at 300 g for 6 min.
with ice cold wash medium containing RPMI, 5% FCS and
1% sodium azide (Sigma). 100 µl of GAM-FITC (goat-
antimouse Ig conjugated to FITC) (12.5 µg/ml) was added
to the cell button, vortexed and incubated on ice for 30–
45 min. Tubes were then washed 3 times at 300 g for 6
min. with cold wash medium (containing 1% azide).
Finally, cells were resuspended in 0.5 ml RPMI (no FCS)
and 1% paraformaldehyde (Sigma). Samples were ana-
lyzed on a Becton Dickinson FACS IV instrument, using
an argon-ion laser running at 350 mW with the wave-
length of excitation set at 488 nm and a 530/30 bandpass
emission filter. Histograms were displayed on a 256-chan-
nel log scale. Uniform cell-sized quantitative fluorescent
microbead standards (Simply Cellular R, Flow Cytometry
Standards Corp., Research Triangle Park, NC) were used
to calibrate the instrument. The percentage of cells
expressing surface antigen was determined using flow
cytometric analysis. In the analysis of the flow cytometry
data, a lower gate channel was set on the negative control
sample so that 5% of the total cells lay above the gate. The
same gate was set on each test sample, and the percentage
of positive cells which lay above the gate was determined.
This number, after 5 % of the negative population was
subtracted from it, was reported as the percent positive
cells in each test sample. The mean log fluorescence chan-
nel was determined for the cells which lay above the gate
channel. Further details are described in the Results sec-
tion. The percent positive cells was related to the relative
fluorescence intensity of the positive cell population.
Quantitation of the number of mAb binding sites on target 
cells
The level of target cell surface antigens was quantitated by
determining the number of antibodies bound by measur-
ing the effective fluorescence/protein (F/P) ratios. The F/P
ratio (as determined by absorbance) is the number of flu-
orescein molecules conjugated to an antibody molecule.
The effective F/P ratio is the average fluorescence intensity
in Molecules of Equivalent Soluble Fluorochrome (MESF)
per antibody molecule. The FACS was calibrated for each
experiment in terms of MESF per channel with the FCSC
Quantum Kit (Flow Cytometry Standards Corp.). These
standards consist of fluorescein molecules covalently
bound to alkyl spacer groups on the exterior of uniform
5.8  µm hydrophobic polymeric microbeads. Their size
and range of fluorescence intensity was optimized for
analysis of common surface markers on peripheral blood
lymphocytes. For each mAb studied, the fluorescence
intensity in MESF was determined using the calibration
curve and the peak fluorescence channel number
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number of binding sites on the microbead to give the
effective F/P ratio.
Target cells were labelled and analysed on the FACS IV
using the same indirect immunofluorescence technique as
used for the microbeads. The mean channel number was
used to obtain the MESF value again from the calibration
curve, and this value was divided by the F/P ratio for the
particular mAb to give the actual number of mAb binding
sites on the target cell surface.
Microscopic enumeration of LAK cell-target conjugates
Lymphocyte-target cell conjugates were analyzed visually
using a modification of the method described by Pross
[42]. IL-2 activated lymphocytes (1 × 106 in 1 ml) and tar-
get cells (1 × 106 in 1 ml) were mixed in ice-cold PBS and
centrifuged at 200 g for 8 min in a 5 ml tube. After incu-
bation for 25 min. on ice, the 1 ml cell pellet were
removed, and gently resuspended. 50 µl conjugate sus-
pension were mixed with 200 µl trypan blue, and an aliq-
uot was transferred to a modified Cunningham chamber
[42]. The percentage of conjugates was determined by
counting the percentage of LAK cells attached to target
cells using a phase contrast microscope. Dead cells stained
with the trypan blue dye were also counted. Free lym-
phocytes, lymphocyte-target conjugates, free targets, and
target-lymphocyte conjugates were counted for at least
200 lymphocytes.
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